MENU
+Compare
TCRX
Stock ticker: NASDAQ
AS OF
May 13 closing price
Price
$1.33
Change
-$0.04 (-2.92%)
Capitalization
75.27M

TCRX TScan Therapeutics Forecast, Technical & Fundamental Analysis

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer... Show more

TCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for TCRX with price predictions
May 13, 2025

TCRX in upward trend: price expected to rise as it breaks its lower Bollinger Band on May 09, 2025

TCRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 29 cases where TCRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TCRX advanced for three days, in of 178 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for TCRX moved out of overbought territory on April 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on May 05, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on TCRX as a result. In of 66 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for TCRX turned negative on May 07, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .

TCRX moved below its 50-day moving average on April 25, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TCRX crossed bearishly below the 50-day moving average on May 07, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for TCRX entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.358) is normal, around the industry mean (14.386). P/E Ratio (0.000) is within average values for comparable stocks, (64.760). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.146). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (36.364) is also within normal values, averaging (254.479).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TCRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
TCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

TCRX is expected to report earnings to fall 214.73% to -29 cents per share on August 13

TScan Therapeutics TCRX Stock Earnings Reports
Q2'25
Est.
$-0.30
Q1'25
Beat
by $0.54
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.06
Q2'24
Est.
$-0.28
The last earnings report on May 06 showed earnings per share of 25 cents, beating the estimate of -28 cents. With 221.55K shares outstanding, the current market capitalization sits at 75.27M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
830 Winter Street
Phone
+1 857 399-9500
Employees
154
Web
https://www.tscan.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA334.0715.69
+4.93%
Tesla
BTC.X104169.8100001356.851600
+1.32%
Bitcoin cryptocurrency
GME28.390.34
+1.21%
GameStop Corp
AAPL212.932.14
+1.02%
Apple
SPY586.843.85
+0.66%
SPDR® S&P 500® ETF

TCRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TCRX has been loosely correlated with FATE. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if TCRX jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TCRX
1D Price
Change %
TCRX100%
+7.87%
FATE - TCRX
46%
Loosely correlated
+2.88%
IMNM - TCRX
45%
Loosely correlated
+6.43%
PRME - TCRX
44%
Loosely correlated
+3.08%
IDYA - TCRX
43%
Loosely correlated
+5.34%
CRSP - TCRX
42%
Loosely correlated
+5.53%
More